A verification-first resource
A facility’s statement that it is “licensed” is not proof that ibogaine treatment is lawful, medically regulated, or safe. Treat the phrase as a claim to unpack—not a conclusion.
Start with the evidence
Facility · clinician · drug · response plan
A licensed ibogaine facility may be describing a general medical-clinic authorization, a sanitary license, a physician’s medical license, a business permit, or private accreditation. Those are not interchangeable.
A residential treatment center license does not necessarily authorize medical treatment. A physician credential does not necessarily authorize possession or administration of ibogaine. Research approval does not mean an ibogaine clinic can market routine ibogaine treatment to the public.
Begin by asking who issued the authorization, what legal entity holds it, what it permits, and whether the document can be independently checked. This clinic-comparison methodology is useful only when the underlying records are named rather than implied.
Ibogaine is associated with serious cardiac risk. The general pharmacology of ibogaine provides context for why legal claims cannot replace rigorous screening, medical staff, and patient safety safeguards.
Before / after verification
“We are a licensed ibogaine clinic” says little without a regulator, license number, legal entity, scope, named physician, and clear explanation of ibogaine’s legal status.
The ibogaine facility supplies its COFEPRIS documentation, clinician Cédula Profesional, medical director details, pre-screening process, cardiac monitoring plan, and emergency transfer procedure.
Jurisdiction first
Ibogaine remains an unscheduled substance in Mexico rather than an explicitly approved pharmaceutical. That means a clinic in Mexico cannot accurately hold a license specifically for ibogaine administration in the way an approved prescription medicine is licensed.
Mexico can still require a legitimate clinical setting to operate through an Aviso de Funcionamiento or Licencia Sanitaria issued by COFEPRIS. Ask the ibogaine clinic which document it holds, whether it applies to the actual treatment center, and whether its stated scope covers the services offered.
New Zealand classified ibogaine as a prescription medicine under the Medicines Act in 2009, making it one of the few jurisdictions where registered medical doctors can legally prescribe it. A country-by-country legal overview can help distinguish this framework from Mexico, Costa Rica, and the Bahamas.
In the United States, ibogaine is a Schedule I controlled substance under the Controlled Substances Act, with no federally accepted medical use. The DEA scheduling explanation clarifies why a U.S. research reference is not a commercial ibogaine treatment license. The U.S. legal-status discussion is another prompt to ask exactly what a provider means by “legal.”
The operating record
Request the facility’s sanitary license or Aviso de Funcionamiento, the issuing authority, document number, legal entity, and the physical location it covers. COFEPRIS paperwork should be relevant to the treatment center actually providing care.
Medical practitioners in Mexico should have a Cédula Profesional that can be independently checked through the SEP National Registry of Professionals. A marketing bio is not verified credentials.
Ask who the medical director is, which licensed medical doctor evaluates risk, and who is physically present during dosing. A board certified anesthesiologist, emergency physician, or internist offers a concrete role to verify.
Private accreditation and peer reviews may be informative, but they do not replace a medical license, health department authorization, or direct confirmation of safety protocols.
A practical clinic verification checklist should lead to actual records, not a promise that the ibogaine facility has already been checked for you.
Clinical people, named
A high-standard ibogaine facility should identify its medical staff before an intake assessment. Ask whether a board certified physician is on-site throughout ibogaine treatment and whether a registered nurse is assigned to continuous monitoring.
The relevant question is not whether a person is called “doctor,” but whether the licensed medical doctor has an active medical license in the jurisdiction, a defined responsibility, and experience appropriate to acute cardiovascular risk.
Ask for the physician’s full professional name and Cédula Profesional in Mexico, then independently verify it. This guide to checking an ibogaine doctor reinforces why background checks and third party verification matter.
The care team should also maintain active ACLS certifications. Advanced cardiac life support training is not a decorative credential: it is central when a patient develops an unstable rhythm, rapid changes in vital signs, or requires emergency transfer.
Cardiovascular standard
“A normal-looking room is not evidence of a clinical setting. The evidence is the protocol: ECG, electrolyte panel, telemetry, trained staff, equipment, and a transfer plan.”
Ibogaine blocks hERG potassium channels in cardiac myocytes, delaying ventricular repolarization and creating QT prolongation risk. That risk explains why an ECG or EKG is not optional paperwork before ibogaine treatment.
A baseline QTc exceeding 450 milliseconds in men or 460 milliseconds in women is an absolute clinical contraindication because of the risk of Torsades de Pointes. An ibogaine clinic should state how it evaluates the ECG, who interprets the EKG, and how it responds to a concerning result.
Continuous cardiac monitoring during administration should include multi-lead telemetry, repeated vital signs, and medical staff who can identify a changing rhythm. The clinical overview of long QT syndrome helps explain why QT prolongation requires careful risk assessment.
A legitimate ibogaine facility maintains immediate access to intravenous magnesium sulfate and a functioning biphasic defibrillator. It should be able to explain where the defibrillator is, who operates it, and how ACLS and advanced cardiac life support are activated.
Screen before dosing
Rigorous screening starts before travel and continues with an intake assessment. Pre-screening should identify contraindications, current medications, substance use disorder history, opiate addiction, drug interactions, and the limits of any medical clearance.
A comprehensive metabolic panel should evaluate potassium and magnesium. Low potassium or magnesium can increase arrhythmia risk, particularly where QT prolongation is already a concern. An electrolyte panel is a basic patient safety measure, not an upgrade.
Hepatic screening through a liver panel also matters because ibogaine is extensively metabolized through CYP2D6 into noribogaine. The ibogaine facility should explain how liver function, dosage, and drug interactions are evaluated by a physician.
Pre-treatment protocols should exclude active schizophrenia, bipolar disorder with mania, or severe active psychosis. A treatment center should not minimize psychiatric contraindications simply because a person is seeking help for opiate addiction or another substance use disorder.
For a wider view of the clinical questions involved, this explanation of ibogaine treatment considerations can help turn general concerns into specific questions for a medical director.
When minutes matter
A credible ibogaine clinic maintains a documented emergency transfer protocol rather than relying on a verbal assurance that help is nearby.
Ask for the nearest hospital, the route, realistic travel time, and whether the receiving facility is a licensed secondary or tertiary hospital.
Reliable centers retain an emergency vehicle or dedicated ambulance service, direct transfer arrangements, and medical staff able to stabilize a patient before emergency transfer.
A verifiable emergency transfer pathway should reach the nearest hospital within roughly 15 to 20 minutes. A municipal dispatch number alone is not the same as hospital access, an ambulance agreement, or ICU capability.
Signals to slow down
Red flags include refusing to name the legal entity, declining to provide a sanitary license or aviso de funcionamiento, claiming that COFEPRIS has “approved ibogaine,” or presenting generic accreditation as if it were government authorization.
Other red flags are no medical director, no board certified physician present during dosing, vague claims about cardiac monitoring, no baseline ECG or EKG, no electrolyte panel, no discussion of QT prolongation, or no clear emergency transfer plan.
Be cautious if an unregulated ibogaine clinic dismisses contraindications, guarantees outcomes for opiate addiction, minimizes fatalities, or treats questions about medical clearance as obstacles rather than patient safety safeguards.
A useful account of ibogaine treatment risks can help frame why a treatment center needs transparent safety protocols. Similarly, this guide on finding a legitimate clinic supports a verification mindset rather than reliance on polished claims.
About this resource
How this independent resource approaches verification is simple: separate what can be documented from what is merely asserted. Ibogaine License Guide does not certify an ibogaine facility or provide medical clearance.
People looking for structured information can also review our verification guidance materials alongside direct regulator records. For location-specific context, the overview at ibogaine centers in Mexico may help identify the questions a prospective patient should ask.
For additional context on the types of claims that can appear around treatment locations, this overview of ibogaine treatment centers can help keep the distinction between advertising and verifiable operations in view.
Ask for specifics
A facility should answer these questions without reframing them as distrust. The more consequential the treatment, the more appropriate it is to request verified credentials and third party verification.
After the dosing window
Ibogaine treatment does not end when acute cardiac monitoring stops. Ask the treatment center what post-treatment care includes, who follows up on medical concerns, and whether aftercare is coordinated with a patient’s existing clinicians.
Clear aftercare planning should address ongoing substance use disorder support, medication questions, emotional changes, travel readiness, and reasons to seek urgent care. Informed consent should describe the distinction between medical monitoring at the ibogaine clinic and longer-term integration support.
Where medical tourism is involved, practical continuity matters even more. Costa Rica, Mexico, the Bahamas, and New Zealand have different legal status and care contexts; a patient should leave with records that support post-treatment care at home.
For another perspective on choosing a setting, this guide to evaluating an ibogaine clinic emphasizes questions about the whole care pathway, not only the day of dosing.
Verification FAQ
Ask for the operator’s legal name, the COFEPRIS document type and number, its scope, and its physical address. An Aviso de Funcionamiento or sanitary license can support lawful operation as a medical or surgical facility, but it does not turn ibogaine into an approved pharmaceutical. Confirm the treating physician’s Cédula Profesional independently and ask what authority the ibogaine clinic relies on for its exact services.
Look for a named medical director, a licensed medical doctor physically present during treatment, and medical staff with active ACLS credentials. A board certified anesthesiologist, emergency physician, or internist may be appropriate for the acute risk profile. Confirm the physician’s medical license, the registered nurse role, and who performs medical clearance and continuous monitoring.
Ibogaine can cause QT prolongation, and abnormal rhythms can develop quickly. A responsible clinical setting describes baseline ECG or EKG review, telemetry, electrolyte panel testing, potassium and magnesium correction, a defibrillator, ACLS-capable medical staff, and a documented emergency transfer plan. The framework for evaluating clinic claims is useful when comparing those details.
Warning signs include an unregulated operation that will not disclose its sanitary license, medical license, physician, ECG or EKG process, cardiac monitoring, hospital relationship, emergency vehicle, or safety protocols. Claims that iboga is harmless, that contraindications do not apply, or that fatalities are irrelevant should prompt caution and independent review.
A final standard
A credible ibogaine facility can identify its authorizations, medical staff, screening, cardiac monitoring, emergency transfer capacity, and aftercare process. If it cannot, the claim remains unverified.
Use the verification framework